Network pharmacology approach to investigate the multitarget mechanisms of Zhishi Rhubarb Soup on acute cerebral infarction

Pharm Biol. 2022 Dec;60(1):1394-1406. doi: 10.1080/13880209.2022.2103718.

Abstract

Context: Zhishi Rhubarb Soup (ZRS) is a traditional Chinese medicine formula used in the clinic to treat acute cerebral infarction (ACI) for many years. However, the exact mechanism of the treatment remains unclear.

Objective: This study elucidates the multitarget mechanisms underlying the effects of ZRS on ACI using network pharmacology analysis and verify its effect by performing animal experiments.

Materials and methods: Using the network pharmacology approach, the multiple components, critical targets and potential mechanisms of ZRS against ACI were investigated. Six herbal names of ZRS and 'acute cerebral infarction' were used as keywords to search the relevant databases. In addition, we established the MCAO model to verify the results of network pharmacology enrichment analysis. ZRS (10 g crude drug/kg) was gavaged once per day for 7 consecutive days beginning 3 h after model establishment. After ZRS treatment, TTC staining, Western blot analysis, IHC and ELISA were conducted to further explore the mechanism of ZRS intervention in ACI.

Results: The network pharmacology approach identified 69 key targets, 10 core genes and 169 signalling pathways involved in the treatment of ACI with ZRS. In vivo experiment showed that ZRS treatment significantly reduced cerebral infarction volume (42.76%). It also reduced the expression level of AGE, RAGE and P65; and inhibited the expression of inflammatory MMP-9 and IFN-γ.

Conclusions: This study demonstrated that ZRS improved cerebral ischaemic injury by inhibiting neuroinflammation partly via the AGE-RAGE signalling pathway. It provides a theoretical basis for the clinical application of ZRS in the treatment of ACI.

Keywords: Ischaemic stroke; mechanism of action; signalling pathways; traditional Chinese medicine formula.

MeSH terms

  • Animals
  • Brain Ischemia* / drug therapy
  • Cerebral Infarction / drug therapy
  • Drugs, Chinese Herbal* / pharmacology
  • Drugs, Chinese Herbal* / therapeutic use
  • Network Pharmacology
  • Rheum*
  • Stroke* / drug therapy

Substances

  • Drugs, Chinese Herbal

Grants and funding

The research is financially supported by the Nanjing Municipal Health Commission Fund Project (Grant Number YKK19098), Nanjing TCM Youth Talent Training Program (Grant Number ZYQ20004) and Jiangsu Province Graduate Experimental Innovation Plan in 2022 (Grant Number SJCX22-0821).